Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARTV NASDAQ:CRON NASDAQ:CVAC NASDAQ:SVRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARTVArtiva Biotherapeutics$10.68+1.7%$8.11$1.47▼$14.53$259.52M2.86644,617 shs389,628 shsCRONCronos Group$2.74+0.4%$2.59$1.84▼$3.43$1.03B0.872.27 million shs1.22 million shsCVACCureVac$4.66$4.66$3.13▼$5.72$1.05B1.77992,546 shsN/ASVRASavara$5.27$5.36$1.89▼$7.01$1.08B0.281.19 million shs1.32 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARTVArtiva Biotherapeutics+1.71%-14.70%+42.59%+167.00%+490.06%CRONCronos Group+0.37%+6.61%+6.61%+5.38%+33.01%CVACCureVac0.00%0.00%0.00%0.00%+38.28%SVRASavara0.00%+2.13%-13.18%-5.89%+76.25%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARTVArtiva Biotherapeutics$10.68+1.7%$8.11$1.47▼$14.53$259.52M2.86644,617 shs389,628 shsCRONCronos Group$2.74+0.4%$2.59$1.84▼$3.43$1.03B0.872.27 million shs1.22 million shsCVACCureVac$4.66$4.66$3.13▼$5.72$1.05B1.77992,546 shsN/ASVRASavara$5.27$5.36$1.89▼$7.01$1.08B0.281.19 million shs1.32 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARTVArtiva Biotherapeutics+1.71%-14.70%+42.59%+167.00%+490.06%CRONCronos Group+0.37%+6.61%+6.61%+5.38%+33.01%CVACCureVac0.00%0.00%0.00%0.00%+38.28%SVRASavara0.00%+2.13%-13.18%-5.89%+76.25%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARTVArtiva Biotherapeutics 2.83Moderate Buy$39.00265.17% UpsideCRONCronos Group 2.20Hold$2.30-16.06% DownsideCVACCureVac 1.80Reduce$6.8346.64% UpsideSVRASavara 2.78Moderate Buy$9.1373.15% UpsideCurrent Analyst Ratings BreakdownLatest ARTV, CVAC, CRON, and SVRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2026CRONCronos Group TD SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/12/2026ARTVArtiva Biotherapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$18.00 ➝ $41.005/11/2026ARTVArtiva Biotherapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$10.00 ➝ $40.005/11/2026ARTVArtiva Biotherapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$23.00 ➝ $40.005/8/2026ARTVArtiva Biotherapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$15.00 ➝ $35.005/4/2026ARTVArtiva Biotherapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$18.004/24/2026ARTVArtiva Biotherapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/24/2026SVRASavara OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$9.00 ➝ $11.004/21/2026SVRASavara Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/16/2026SVRASavara William BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$10.003/16/2026SVRASavara HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 5/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARTVArtiva Biotherapeutics$250K1,056.04N/AN/A$3.55 per share3.01CRONCronos Group$146.59M7.03$0.01 per share217.76$2.99 per share0.92CVACCureVac$70.74M14.78$0.99 per share4.73$3.36 per share1.39SVRASavaraN/AN/AN/AN/A$0.86 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARTVArtiva Biotherapeutics-$83.86M-$3.54N/AN/AN/AN/A-73.15%-62.74%N/ACRONCronos Group-$9.45M$0.01274.27N/AN/A-1.14%-1.26%-1.20%N/ACVACCureVac$175.50M$0.726.47N/AN/A199.92%-23.03%-19.09%N/ASVRASavara-$118.84M-$0.56N/AN/AN/AN/A-87.19%-66.42%N/ALatest ARTV, CVAC, CRON, and SVRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026SVRASavara-$0.14-$0.15-$0.01-$0.15$0.50 millionN/A5/11/2026Q1 2026CRONCronos Group$0.01$0.01N/A$0.04$42.20 million$58.97 million5/8/2026Q1 2026ARTVArtiva Biotherapeutics-$0.88-$0.95-$0.07-$0.95N/AN/A3/13/2026Q4 2025SVRASavara-$0.12-$0.13-$0.01-$0.13N/AN/A3/10/2026Q4 2025ARTVArtiva Biotherapeutics-$0.87-$0.84+$0.03-$0.84N/AN/A2/26/2026Q4 2025CRONCronos Group$0.01$0.02+$0.01N/A$38.51 million$58.39 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthARTVArtiva BiotherapeuticsN/AN/AN/AN/AN/ACRONCronos GroupN/AN/AN/AN/AN/ACVACCureVacN/AN/AN/AN/AN/ASVRASavaraN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARTVArtiva BiotherapeuticsN/A8.168.61CRONCronos GroupN/A21.8718.62CVACCureVac0.033.703.69SVRASavara0.1713.4711.85Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARTVArtiva BiotherapeuticsN/ACRONCronos Group8.71%CVACCureVac17.26%SVRASavara87.93%Insider OwnershipCompanyInsider OwnershipARTVArtiva Biotherapeutics21.40%CRONCronos Group7.80%CVACCureVac2.15%SVRASavara5.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARTVArtiva Biotherapeutics8124.72 million19.43 millionN/ACRONCronos Group450376.27 million346.92 millionOptionableCVACCureVac880224.34 million219.52 millionOptionableSVRASavara20204.93 million194.06 millionOptionableARTV, CVAC, CRON, and SVRA HeadlinesRecent News About These CompaniesSavara Reports First Quarter Financial Results and Provides Business UpdateMay 12 at 4:05 PM | businesswire.comSavara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor ConferenceMay 12 at 12:30 PM | cadillacnews.comCSwedbank AB Has $5.13 Million Position in Savara Inc. $SVRAMay 10, 2026 | marketbeat.comNan Fung Trinity HK Ltd. Takes $10.18 Million Position in Savara Inc. $SVRAMay 10, 2026 | marketbeat.comSavara Inc. $SVRA Position Boosted by F m Investments LLCMay 10, 2026 | marketbeat.comSavara (SVRA) to Release Earnings on TuesdayMay 5, 2026 | marketbeat.comAssessing Savara (SVRA) Valuation After FDA Extends Priority Review For MolgramostimApril 26, 2026 | finance.yahoo.comSavara (NASDAQ:SVRA) Coverage Initiated by Analysts at OppenheimerApril 24, 2026 | marketbeat.comSavara Inc. (NASDAQ:SVRA) Given Average Recommendation of "Moderate Buy" by BrokeragesApril 21, 2026 | marketbeat.comFY2026 EPS Estimates for Savara Decreased by Lifesci CapitalApril 20, 2026 | marketbeat.comSavara (NASDAQ:SVRA) Strengthens Market Presence In Nasdaq Today Biotech SegmentApril 19, 2026 | kalkinemedia.comKSavara (NASDAQ:SVRA) Stock Price Up 2.5% - Here's WhyApril 17, 2026 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Savara (SVRA) and Rhythm Pharmaceuticals (RYTM)April 17, 2026 | theglobeandmail.comSavara Announces New Employment Inducement GrantApril 17, 2026 | businesswire.comSavara gets FDA review extension for lead assetApril 16, 2026 | seekingalpha.comSavara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application ...April 15, 2026 | uk.finance.yahoo.comSVRA stock slips post-market after FDA delays decision on pulmonary therapyApril 15, 2026 | msn.comSavara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)April 15, 2026 | businesswire.comSavara To Present New Data at the American Thoracic Society (ATS) 2026 International ConferenceApril 14, 2026 | businesswire.comSavara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune ...April 7, 2026 | finance.yahoo.comSavara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)April 7, 2026 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesASML Falls Post-Earnings, Chip-Making Expansion Anchors OutlookBy Leo Miller | April 16, 2026STMicronelectronics Sends Industrial Chips Into OverdriveBy Thomas Hughes | April 24, 2026The DRAM Shake-Up: Samsung Stumbles, Micron Chases $1000By Jeffrey Neal Johnson | May 12, 2026XLK in Rebound Mode, But Can It Reach Fresh Highs?By Thomas Hughes | April 16, 2026Micron Investors Face a High-Stakes Moment After the Latest RallyBy Thomas Hughes | May 13, 2026ARTV, CVAC, CRON, and SVRA Company DescriptionsArtiva Biotherapeutics NASDAQ:ARTV$10.68 +0.18 (+1.71%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$10.74 +0.05 (+0.51%) As of 05:46 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.Cronos Group NASDAQ:CRON$2.74 +0.01 (+0.37%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$2.76 +0.02 (+0.58%) As of 04:34 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.CureVac NASDAQ:CVAC$4.66 0.00 (0.00%) As of 05/13/2026CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.Savara NASDAQ:SVRA$5.27 0.00 (0.00%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$5.16 -0.11 (-1.99%) As of 05:44 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas YETI Rallies After Earnings Beat and Raised Outlook Cisco’s Vertical Rally May Still Be in the Early Innings Dividend Growth or High Yield: The Income Investor's Bet Nebius Upside Expands as AI Feedback Loop Intensifies Oklo Stock Could Be Ready for Another Massive Run Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell Qualcomm Stock Doubles: New Era? Or Another False Start? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
